Back to profiles

Medable

Medable, founded in 2012 in Palo Alto, has raised over $521 million in funding and achieved a valuation of $2.1 billion as of October 2021. Backed by prominent investors including Sapphire Ventures, Tiger Global Management, and Blackstone Growth, the company’s largest round was a Series D of $304 million. Medable’s cloud-based platform streamlines clinical research through tools such as eConsent, telemonitoring, and remote patient engagement, operating across more than 60 countries. By enabling decentralized trials and leveraging AI-driven workflows, Medable is transforming how life-science companies design, conduct, and analyze clinical studies.